半年过去,药明巨诺收入仅超1亿元,“天价抗癌药”商业困局难破!

医药研究社
Aug 28, 2025

CAR-T产品的商业化考验。来源|医药研究社前沿抗癌方案中,CAR-T(嵌合抗原受体T细胞)正备受关注。弗若斯特沙利文预测,全球CAR-T细胞疗法市场销售价值将在2030年达到218亿美元,2021年至2030年的年复合增长率为34.8%。前景似乎不错,但目前以CAR-T为主线的药企却很难尝到甜头。典型例子就有药明巨诺。近日该公司发布的财报显示,今年上半年实现收入1.06亿元,同比增加22.5%;...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10